Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528241 · ClinicalTrials.gov registry record · Phase 1
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01528241 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT01528241, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study is designed to characterize the regional distribution of \[11C\] ABP688 in brain by positron emission tomography (PET).
Interventions
- DRUG ABP688
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01528241
The ClinicalTrials.gov registry entry for NCT01528241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABP688 is the first listed.
NCT01528241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01528241 about?
NCT01528241 is a clinical study titled "Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)". This study is designed to characterize the regional distribution of \[11C\] ABP688 in brain by positron emission tomography (PET).
What is the current status of trial NCT01528241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01528241?
The interventions under investigation include: ABP688 (DRUG).
Who is sponsoring clinical trial NCT01528241?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.